Market
Market Opportunity
Over $500m growing WW market due to new indications and new territories
- U.S.
– Very few competitors due to Doxil’s complexity
– Strategic agreement with teir 1 pharma for U.S. comercialization - EU
– Single branded product sold (Caelyx) with no Generic entry
China
– ~$100m market, growing at over 40% annualy
– Price level similar to U.S. / EU
LC101 Addressing Large Unmet Medical Need
Doxorubicin HCL Liposome injection indications
Ovarian Cancer(1) :
- 7th most common cancer and 8th most common cause of death from cancer in women worldwide
- Representing 3.4% (~295K) of cancer cases and 4.4% (~185K) of cancer deaths in 2018
- Predicted 55% increase in incidence and 67% increase in death by 2035 worldwide
Multiple Myeloma Cancer(2) :
- Predicted ~32K new cases and ~13K deaths in 2019 in the U.S.
Metastatic Breast Cancer(2,3):
- Predicted ~270K new cases and 42K deaths in 2019 in the U.S.
(1) Bhatla, N. and Jones, A., 2018, THE WORLD OVARIAN CANCER COALITION ATLAS GLOBALTRENDS IN INCIDENCE, MORTALITY & SURVIVAL April 2018
(2) https://cancerstatisticscenter.cancer.org
(3) Indicated in EU